ArticleApplied biochemistry and biotechnology2026
Characterization and Immunomodulatory Activity of a Sulfated Polysaccharide from Natto-Derived Bacillus subtilis.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Sulfated polysaccharides with significant biological activities were widely applied in functional food, cosmetic, biomedical and pharmaceutical industries. In this study, we established a practical high-throughput screening workflow for sulfated polysaccharide-producing bacteria and applied it to natto-derived isolates. Using this approach, a sulfated polysaccharide produced by Bacillus subtilis var. natto GX10-35 with the yield of 0.86 mg/mL was isolated and a purified polysaccharide fraction, GX10-35-P1, was obtained from its fermentation broth. Chemical analyses showed the sulfate content of the sulfated polysaccharide GX10-35-P1 was 12.02%. Spectroscopic analyses suggests that GX10-35-P1 is a sulfated exopolysaccharide with distinct structural features, with a proposed backbone consisting of α-D-Galp-(1→6)-α-D-Glcp-(1→→6)-α-D-Glcp-(1→→6)-α-D-Glcp-(1→6)-α-D-Galp3S-(1→6)-α-D-Glcp-(1→6)-α-D-Glcp-(1→6)-α-D-Glcp-(1→, indicating it could be classified as an unreported type of water-soluble sulfated exopolysaccharide from bacteria. Moreover, GX10-35-P1 could induce murine macrophage cells RAW264.7 to proliferation, phagocytic, release nitric oxide and promote the mRNA expression of TNF-α, IL-1β, IL-6 and IL-10 cytokines. These results indicate that GX10-35-P1 is a promising bacterial sulfated polysaccharide with potential for further investigation as an immunomodulatory agent.
Indexed as
Identifiers
42709379What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.